Details of the Drug

General Information of Drug (ID: DMBPN4K)

Drug Name
CAR-T cells targeting MucI
Indication
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Phase 1/2 [1]
Glioblastoma multiforme 2A00.0 Phase 1 [2]
Pancreatic cancer 2C10 Phase 1 [3]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D05CSS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mucin-1 (MUC1) TTBHFYQ MUC1_HUMAN CAR-T-Cell-Therapy [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Lung cancer
ICD Disease Classification 2C25.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mucin-1 (MUC1) DTT MUC1 4.59E-01 -0.07 -0.41
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
2 ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
3 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.